1 tering of GD1a or GT1b by using precomplexed antiganglioside Abs.

2 h as nitric oxide, endocaine, cytokines, and antiganglioside antibodies also play significant roles.

3 iatic nerve was performed in the presence of antiganglioside antibodies and fresh human serum as an a

4                           The elimination of antiganglioside antibodies from the circulation through

5                                              Antiganglioside antibodies have long been used in clinic

6          Continuing progress in the field of antiganglioside antibodies is expanding our comprehensio

7 t passively administered and vaccine-induced antiganglioside antibodies prevent outgrowth of micromet

8 -like syndrome, and neuropathy with positive antiganglioside antibodies.

9  of Ranvier is relatively resistant to acute antiganglioside antibody mediated injury over this time

10 lear immune cells and studied the ability of antiganglioside antibody to activate these cells using t

11  exceptionally high cytotoxic potency and an antiganglioside GD2 monoclonal antibody 14G2a.

12 e likely than other GBS patients to have IgG antiganglioside GM1 antibodies and to have had preceding

13                                              Antiganglioside GM1 antibodies were present in a higher

14 s; and (iv) adding highly specific IgG-class antiganglioside mAbs.